Evotec in retinal disease drug research collaboration with academia

youthful eyes
Evotec teams with Technische Universität Dresden’s CRTD to discover novel therapies for retinal diseases.

In a new partnership with the academia—and in a comparatively speaking new therapeutic area for Evotec—the CRO will apply its leading induced pluripotent stem cell (iPSC) technology to identify novel drug candidates for retinal diseases.

The Technische Universität Dresden Center for Regenerative Therapies Dresden (CRTD), also an expert in stem cells, is the other party in the research collaboration and will contribute its expertise in stem cell-based disease modeling. It is currently using its understanding of stem cells, physiological and pathological tissue and organ repair to develop treatments for neurodegenerative, hematological, metabolic and bone diseases.

Using patient-derived iPSCs that can be developed into various cell types contained in the retina, the two parties will build models for drug research in different eye diseases.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“CRTD is a world leader in stem cell-derived modeling of retinal disease and thus fits perfectly into our strategy to continue to build and expand Evotec's unique iPSC based drug discovery platform,” Evotec CSO Cord Dohrmann said in a statement.

RELATED: Evotec and Oxford University hand out first drug discovery awards

The new relationship will be nurtured under Evotec’s non-outsourcing segment called EVT Innovate, which links academic innovation with Evotec’s industrialized drug discovery capabilities to advance early drug assets to the point of potential biopharma company buyouts or new spin-out companies.

Alliances with Yale University and the University of Oxford are existing examples of the platform. One year into operation, the novel £13 million drug discovery partnership Evotec formed with Oxford and the university’s venture fund back in November 2016 has already successfully accelerated 12 drug R&D projects at the university. The project model has also been introduced to Canada in a partnership between Evotec and MaRS Innovation, which has 15 member institutions, with more deals to be announced later.

RELATED: On back of Roche pact, newly formed Ncardia wins iPSC deal with Evotec

The business model looks familiar to Evotec, but the therapeutic area of ophthalmology is perhaps new territory, since its key areas of expertise are in diabetes, oncology, neurodegeneration, pain and inflammation.

Evotec recognizes the potential of global retinal dystrophy market, which includes both rare genetic diseases as well as more common disorders like glaucoma, age-related macular degeneration and diabetic retinopathy. “Whilst cell replacement and gene therapies will likely play an important role in the future, there continues to be a need for small molecule treatments as both monotherapy and in combination with other therapies,” the company said in the statement.

The German CRO has been bulking up its iPSC offerings lately, with new deals signed with Censo Biotechnologies, the Fraunhofer Institute for Molecular Biology and Applied Ecology and the newly merged Ncardia.

Suggested Articles

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.

Scientists at the Broad Institute and the Dana-Farber Cancer Institute identified 49 existing drugs they believe could be repurposed to treat cancer.

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.